Lisata Therapeutics, Inc. (LSTA), Tuesday announced a mutual termination of the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical Co., Ltd., regaining full, exclusive rights to its oncology asset in the Greater China Region.
Following the termination, Lisata will regain the full, exclusive rights to certepetide, an investigational drug designed to activate a novel uptake pathway that enables co-administered or tethered anti-cancer drugs to target and penetrate solid tumors better.
However, Qilu maintains its obligations to complete and wind down its ongoing Phase 2 clinical study, evaluating certepetide in combination with standard-of-care chemotherapy in metastatic pancreatic ductal adenocarcinoma.
Meanwhile, Lisata has agreed to negotiate with Qilu the potential licensing of relevant study data from this trial, as appropriate.
In the pre-market hours, LSTA is moving up 12.53 percent, to $4.58 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.